Research programme: platelet thrombin receptor antagonists - Merck & Co
Alternative Names: PAR-1 antagonists research programme - Merck & Co; Platelet thrombin receptor antagonists research programme - Merck & Co; Research programme: PAR-1 antagonists - Merck & CoLatest Information Update: 26 May 2010
At a glance
- Originator Merck & Co
- Class Small molecules
- Mechanism of Action PAR 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 26 May 2010 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
- 11 Sep 2000 Preclinical development for Thrombosis in USA (Unknown route)